SOC2102
20 Apr 2022
SOC2102
ACTRN12621000479808
A Phase 1a/b, open-label, dose-exploration, combination/ expansion study to evaluate the safety, tolerability and pharmacokinetics of Auceliciclib in advanced solid tumours and in combination with temozolomide in recurrent or newly diagnosed Glioblastoma multiforme (GBM).
Aucentra Therapeutics
Cancer Type | All cancers; Brain; Gynaecological |
---|---|
Trial Type | Treatment |
Phase | Phase I |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2021-06-16 |
Anticipated End Date | 2023-06-30 |
Hospital | Southern Oncology Clinical Research Unit |
---|---|
Clinical Trial Coordinator | Meggan O'Riley |
Meggan.ORiley@socru.org.au | |
Phone | 0491 679 039 |
Principal Investigator | Dr Ganessan Kichenadasse |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs